AR059902A2 - Complejo de factor viii/vwf o factor viii:c - Google Patents

Complejo de factor viii/vwf o factor viii:c

Info

Publication number
AR059902A2
AR059902A2 ARP070101059A ARP070101059A AR059902A2 AR 059902 A2 AR059902 A2 AR 059902A2 AR P070101059 A ARP070101059 A AR P070101059A AR P070101059 A ARP070101059 A AR P070101059A AR 059902 A2 AR059902 A2 AR 059902A2
Authority
AR
Argentina
Prior art keywords
factor
viii
vwf
factor viii
complex
Prior art date
Application number
ARP070101059A
Other languages
English (en)
Inventor
Arthur Mitterer
Bernhard Fischer
Oyvind L Schonberger
Kathrin Thomas-Urban
Friedrich Dorner
Jonhann Eibl
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3487946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR059902(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of AR059902A2 publication Critical patent/AR059902A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a un complejo de factor VIII/vWF obtenible mediante cromatografía de intercambio cationico. Reivindicacion 1: Un complejo Factor VIII/factor von Willebrand (Factor VIII/vWF) caracterizado porque contiene multímeros de alto peso molecular que tienen una actividad vWF específica de al menos 66 U/mg de proteína y una actividad específica de Factor VIII de al menos 500 U/mg de proteína.
ARP070101059A 1997-02-27 2007-03-15 Complejo de factor viii/vwf o factor viii:c AR059902A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0033897A AT406373B (de) 1997-02-27 1997-02-27 Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie

Publications (1)

Publication Number Publication Date
AR059902A2 true AR059902A2 (es) 2008-05-07

Family

ID=3487946

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980100835A AR010121A1 (es) 1997-02-27 1998-02-25 MÉTODO DE RECUPERACIoN DE COMPLEJO DE FACTOR VIII/FACTOR DE VON WILLEWBRAND (COMPLEJO DE FACTOR VIII/VWF) MEDIANTE CROMATOGRAFíA DE INTERCAMBIO CATIoNICO.
ARP070101059A AR059902A2 (es) 1997-02-27 2007-03-15 Complejo de factor viii/vwf o factor viii:c

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP980100835A AR010121A1 (es) 1997-02-27 1998-02-25 MÉTODO DE RECUPERACIoN DE COMPLEJO DE FACTOR VIII/FACTOR DE VON WILLEWBRAND (COMPLEJO DE FACTOR VIII/VWF) MEDIANTE CROMATOGRAFíA DE INTERCAMBIO CATIoNICO.

Country Status (11)

Country Link
US (3) US6831159B1 (es)
EP (1) EP0971958B2 (es)
JP (1) JP4250771B2 (es)
AR (2) AR010121A1 (es)
AT (2) AT406373B (es)
AU (1) AU744919B2 (es)
CA (1) CA2282841C (es)
DE (1) DE59814211D1 (es)
ES (1) ES2306471T5 (es)
NO (2) NO324902B1 (es)
WO (1) WO1998038220A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
ES2298096B1 (es) 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
DK2467399T3 (en) 2009-08-20 2017-01-23 Baxalta Inc Purification of vWF for increased removal of non-lipid-enveloped viruses
WO2011060242A2 (en) 2009-11-13 2011-05-19 Talecris Biotherapeutics, Inc. Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
KR101619865B1 (ko) 2010-07-30 2016-05-11 이엠디 밀리포어 코포레이션 크로마토그래피 매질
SG191186A1 (en) 2010-12-15 2013-07-31 Baxter Int Eluate collection using conductivity gradient
DK3412305T3 (da) * 2011-06-10 2021-03-01 Baxalta GmbH Behandling af koagulationssygdom ved administration af rekombinant vwf
US9534037B2 (en) 2011-08-02 2017-01-03 Baxalta GmbH Systems and methods to increase protein yield from recombinant manufacturing processes
PL2861059T3 (pl) 2012-06-15 2017-10-31 Commw Scient Ind Res Org Wytwarzanie długołańcuchowych wielonienasyconych kwasów tłuszczowych w komórkach roślinnych
EP2925777B1 (en) * 2012-11-30 2019-05-01 Centre for Bioseparation Technology-VIT Monolith-based pseudo-bioaffinity purification methods for factor viii and applications thereof
CN105705516B (zh) * 2013-11-08 2019-11-01 杰特有限公司 浓缩von Willebrand因子或其络合物的方法
NZ721036A (en) 2013-12-18 2023-07-28 Grains Res & Dev Corp Lipid comprising long chain polyunsaturated fatty acids
PH12016502586B1 (en) 2014-06-27 2023-07-19 Commw Scient Ind Res Org Lipid comprising docosapentaenoic acid
EP3188816B1 (en) 2014-09-02 2021-06-09 EMD Millipore Corporation Chromatography media comprising discrete porous bundles of nanofibrils
EP3230299A1 (en) 2014-12-08 2017-10-18 EMD Millipore Corporation Mixed bed ion exchange adsorber
EP4424366A3 (en) 2017-07-07 2024-12-04 Takeda Pharmaceutical Company Limited Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
EA202192140A1 (ru) 2019-02-01 2021-12-15 Такеда Фармасьютикал Компани Лимитед СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
CN114106145B (zh) * 2021-10-22 2023-09-01 山东泰邦生物制品有限公司 一种血源人凝血因子ⅷ/血管性血友病因子复合物生产工艺

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
GB8403473D0 (en) * 1984-02-09 1984-03-14 Special Trustees For St Thomas Purification of factor viii
US5200510A (en) * 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
FR2651437A1 (fr) * 1989-09-05 1991-03-08 Lille Transfusion Sanguine Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total.
NZ237244A (en) * 1990-03-02 1992-10-28 Bio Technology General Corp Cloning and production of human von willebrand factor analogues and compositions thereof
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
IT1256622B (it) * 1992-12-04 1995-12-12 Sclavo Spa Processo per l'estrazione del complesso fattore viii-fattore von willebrand (fviii:c-fvw) da plasma umano totale.
CA2159044A1 (en) 1994-09-26 1996-03-27 Falko-Guenter Falkner Method of quantitating nucleic acids
AT401270B (de) * 1994-09-26 1996-07-25 Immuno Ag Verfahren zur quantifizierung von genomischer dna
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
DE4435392B4 (de) * 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT403765B (de) * 1996-04-12 1998-05-25 Immuno Ag Verfahren zur herstellung einer präparation enthaltend einen hochgereinigten komplex
CA2251558C (en) 1996-04-12 2005-11-22 Immuno Aktiengesellschaft Highly purified factor viii complex
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT406373B (de) 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie

Also Published As

Publication number Publication date
JP4250771B2 (ja) 2009-04-08
CA2282841C (en) 2008-12-02
NO994137L (no) 1999-08-26
CA2282841A1 (en) 1998-09-03
NO324902B1 (no) 2007-12-27
US6953837B2 (en) 2005-10-11
ES2306471T3 (es) 2008-11-01
EP0971958B1 (de) 2008-04-09
ATA33897A (de) 1999-09-15
US6831159B1 (en) 2004-12-14
NO20071357L (no) 1999-08-26
DE59814211D1 (de) 2008-05-21
NO326257B1 (no) 2008-10-27
AT406373B (de) 2000-04-25
ATE391728T1 (de) 2008-04-15
AU744919B2 (en) 2002-03-07
EP0971958A1 (de) 2000-01-19
US20050239171A1 (en) 2005-10-27
ES2306471T5 (es) 2012-06-07
EP0971958B2 (de) 2012-02-08
JP2001517212A (ja) 2001-10-02
US20020058625A1 (en) 2002-05-16
NO994137D0 (no) 1999-08-26
US7648958B2 (en) 2010-01-19
WO1998038220A1 (de) 1998-09-03
AU6080698A (en) 1998-09-18
AR010121A1 (es) 2000-05-17

Similar Documents

Publication Publication Date Title
AR059902A2 (es) Complejo de factor viii/vwf o factor viii:c
Furlan et al. Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers.
NZ330897A (en) Human trk receptors and neurotropic factor inhibitors
DE69629209D1 (de) Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose
ES2196031T3 (es) Derivados peptidicos terapeutico.
EA199800946A1 (ru) Концентрированный препарат антител
ATE223229T1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
LU91448I2 (fr) "panitumumab"
MX9305729A (es) Formulas de proteinas de liberacion sostenida.
DK0503648T3 (da) CD2-bindingsdomæne af lymfocytfunktion-associeret antigen 3
FI943745L (fi) Koostumuksia ja menetelmiä proteiinin rakenteen määrityksiin
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
DK0672138T3 (da) Kimære prokoagulante proteiner
EP0695171A1 (en) GONADOTROPINE CONTAINING FREEZER DRIED DROPS
PT523395E (pt) Regioes sero-reactivas na proteina e1 e e2 de hpv 16
DK0468257T3 (da) Multimer form af human rhinovirusreceptorprotein
ES2181501T3 (es) Composicion cosmetica.
ES2090273T3 (es) Estuche para el dosificado especifico de la angiotensina ii.
BG103968A (en) Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity
DE69127334D1 (de) Verabreichung von Mitteln
FR2717808B1 (fr) Composition cosmétique stable à la lumière.
MX9302614A (es) Receptor de glutamato metabotropico humano y compuestos de dna relacionados.
ES2080060T3 (es) Proteinas que tienen actividad de union a interferon-gamma.
ATE220393T1 (de) Eine heteroethynylen-brücke enthaltende bi- aromatische verbindungen und diese enthaltende pharmazeutische und kosmetische zusammensetzungen
FI952738L (fi) Stabiiliproteiini, fosfolipidikoostumuksia ja menetelmiä

Legal Events

Date Code Title Description
FB Suspension of granting procedure